Your session is about to expire
← Back to Search
Other
AXS-05 for Alzheimer's Disease (ACCORD Trial)
Phase 3
Waitlist Available
Research Sponsored by Axsome Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial is testing AXS-05, a medication, to see if it can help reduce agitation in people with Alzheimer's disease by balancing brain chemicals. AXS-05 has shown potential for treating agitation in Alzheimer's disease, especially in patients with comorbid depression. Patients will first try the medication for a few weeks, and those who respond well will either continue the medication or switch to an alternative for several months.
Eligible Conditions
- Alzheimer's Disease
- Agitation in Dementia
- Psychomotor Agitation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2019 Phase 3 trial • 327 Patients • NCT0401970429%
All Others, occurring in <5% of Subjects
16%
Dizziness
13%
Nausea
8%
Headache
7%
Diarrhea
7%
Somnolence
6%
Dry mouth
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
AXS-05
Placebo
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AXS-05Experimental Treatment1 Intervention
Up to 26 weeks in double-blind period
Group II: PlaceboPlacebo Group1 Intervention
Up to 26 weeks in double-blind period
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AXS-05
2018
Completed Phase 3
~1390
Find a Location
Who is running the clinical trial?
Axsome Therapeutics, Inc.Lead Sponsor
31 Previous Clinical Trials
10,749 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger